Hyperactivity News and Research

RSS

Early interference in entorhinal cortex may halt progression of Alzheimer's disease

New research is helping to unravel the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain. The research, published by Cell Press in the November 4th issue of the journal Neuron, follows disease progression from a vulnerable brain region that is affected early in the disease to interconnected brain regions that are affected in later stages. The findings may contribute to design of therapeutic interventions as targeting the brain region where AD originates would be simpler than targeting multiple brain areas.

4 Nov 2010

Scientists identify events that causes AD progression

Scientists at the Gladstone Institute of Neurological Disease (GIND) have offered new information about the events that underlie the "spread" of Alzheimer's disease (AD) throughout the brain.

4 Nov 2010

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA (methylphenidate HCl extended-release tablets).

3 Nov 2010

Watson enters exclusive agreement with OMJPI to market authorized generic Concerta

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

2 Nov 2010

CONCERTA improves handwriting performance in children with ADHD: Study

Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.

30 Oct 2010

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

Mary Ann Liebert launches Brain Connectivity journal

Mary Ann Liebert, Inc. announces the release of a new peer-reviewed journal in an expanding area of systems neuroscience, Brain Connectivity. This timely new journal is positioned to become the premier source of cutting-edge basic and clinical neuroscience research aimed at better understanding of structural and functional connections in the brain and how these connections are altered by neurological disorders.

29 Oct 2010

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Shire plc the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone.

29 Oct 2010

Safety tips to reduce risk of lead exposure

With more than 2,700 children having elevated blood lead levels in 2009, the Department of Health today reminds parents to test young children for lead exposure, especially during National Lead Poisoning Prevention Week, Oct. 24-30.

25 Oct 2010

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

UCSF scientists have received two grants from the California Institutefor Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure. The goal of the grants is for researchers to make significant strides toward the development of potential therapies within the next three years.

25 Oct 2010

Health law's new patient-centered outcomes board takes shape; More insurance waiver requests expected

The Washington Post reports on a new entity: the Board of Governors of the Patient Centered Outcomes Research Institute. "If you're not familiar with the board, you're not alone. Created by the health-care overhaul law, it's one of the newest and least known panels in government. But the work of its 21 members, if successful, could increase the public's knowledge of medical treatments for everything from attention deficit and hyperactivity disorder to cancer.

18 Oct 2010

Researchers identify new paradigm for regulation of alternative splicing

How a T cell decides to make protein X, Y, or Z can have profound effects for fighting foreign invaders or staving off dire autoimmune reactions. Researchers at the University of Pennsylvania School of Medicine have identified the steps that control how different forms of an immune cell protein called CD45, which is critical for activating the immune system when faced with pathogens, are controlled in the arc of a body's immune response.

18 Oct 2010

First Edition: October 15, 2010

Today's top stories from major news organizations report on the effort by 20 states to challenge the federal health law, a new federal panel to inform consumers about health care options and the struggle to pay for cancer care.

15 Oct 2010

Developmental-Behavioral Pediatrics Research Network to focus on neurodevelopmental disabilities

Recognizing both medical progress and unmet needs in the field of developmental disabilities, The Children's Hospital of Philadelphia will house the Network Coordinating Center for a newly established collaborative organization, the Developmental-Behavioral Pediatrics Research Network.

14 Oct 2010

Researchers use brain imaging to differentiate pediatric bipolar disorder, ADHD

Researchers at the University of Illinois at Chicago are the first to use brain imaging to examine the effects of emotion on working memory function in children with pediatric bipolar disorder or attention deficit hyperactivity disorder.

13 Oct 2010

NCQA recertifies Lilly's online Health Education Answers program

Lilly's Health Education Answers program, an interactive online health and wellness tool, has received Health Information Product Recertification from the National Committee for Quality Assurance (NCQA).

11 Oct 2010

More than 2 hours of screen viewing associated with psychological difficulties in children

Children who spend longer than two hours in front of a computer or television screen are more likely to suffer psychological difficulties, regardless of how physically active they are.

11 Oct 2010

Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD

Targacept, Inc. today announced top-line results from a Phase 2 clinical trial of AZD1446 conducted by AstraZeneca in adults with attention deficit/hyperactivity disorder (ADHD).

8 Oct 2010

Study: 18% of children with ADHD suffered from depression as adolescents

Children diagnosed with attention deficit/hyperactivity disorder (ADHD) at ages 4 to 6 are more likely to suffer from depression as adolescents than those who did not have ADHD at that age, according to a long-term study published in the October issue of the Archives of General Psychiatry. Although it was an uncommon occurrence, the children with ADHD also were somewhat more likely to think about or attempt suicide as adolescents.

5 Oct 2010

Study finds children with ADHD have high risk for adolescent depression

Young children with attention-deficit/hyperactivity disorder (ADHD) appear to be at greater risk for adolescent depression and/or suicide attempts five to 13 years after diagnosis, according to a report in the October issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Oct 2010

Hyperactivity News and Research

Early interference in entorhinal cortex may halt progression of Alzheimer's disease

Scientists identify events that causes AD progression

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Watson enters exclusive agreement with OMJPI to market authorized generic Concerta

CONCERTA improves handwriting performance in children with ADHD: Study

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Mary Ann Liebert launches Brain Connectivity journal

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Safety tips to reduce risk of lead exposure

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

Health law's new patient-centered outcomes board takes shape; More insurance waiver requests expected

Researchers identify new paradigm for regulation of alternative splicing

First Edition: October 15, 2010

Developmental-Behavioral Pediatrics Research Network to focus on neurodevelopmental disabilities

Researchers use brain imaging to differentiate pediatric bipolar disorder, ADHD

NCQA recertifies Lilly's online Health Education Answers program

More than 2 hours of screen viewing associated with psychological difficulties in children

Targacept announces top-line results from AZD1446 Phase 2 clinical trial for ADHD

Study: 18% of children with ADHD suffered from depression as adolescents

Study finds children with ADHD have high risk for adolescent depression

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News